- Home
- EBS vs IMAB Comparison
EBS vs IMAB Comparison
Compare EBS & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- IMAB
- Stock Information
- Founded
- EBS 1998
- IMAB 2014
- Country
- EBS United States
- IMAB United States
- Employees
- EBS N/A
- IMAB N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- IMAB Health Care
- Exchange
- EBS Nasdaq
- IMAB Nasdaq
- Market Cap
- EBS 359.3M
- IMAB 384.6M
- IPO Year
- EBS 2006
- IMAB 2020
- Fundamental
- Price
- EBS $8.15
- IMAB $4.09
- Analyst Decision
- EBS Strong Buy
- IMAB Strong Buy
- Analyst Count
- EBS 3
- IMAB 5
- Target Price
- EBS $14.33
- IMAB $6.80
- AVG Volume (30 Days)
- EBS 1.0M
- IMAB 2.0M
- Earning Date
- EBS 11-05-2025
- IMAB 11-02-2025
- Dividend Yield
- EBS N/A
- IMAB N/A
- EPS Growth
- EBS N/A
- IMAB N/A
- EPS
- EBS 2.53
- IMAB N/A
- Revenue
- EBS $851,600,000.00
- IMAB N/A
- Revenue This Year
- EBS N/A
- IMAB N/A
- Revenue Next Year
- EBS $19.24
- IMAB N/A
- P/E Ratio
- EBS $3.22
- IMAB N/A
- Revenue Growth
- EBS N/A
- IMAB N/A
- 52 Week Low
- EBS $4.02
- IMAB $0.60
- 52 Week High
- EBS $12.73
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- EBS 51.40
- IMAB 50.05
- Support Level
- EBS $7.45
- IMAB $3.20
- Resistance Level
- EBS $8.62
- IMAB $4.64
- Average True Range (ATR)
- EBS 0.40
- IMAB 0.45
- MACD
- EBS -0.10
- IMAB -0.14
- Stochastic Oscillator
- EBS 38.46
- IMAB 40.27
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).